Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy
Author:
Affiliation:
1. Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska 68198-6805, United States
Funder
National Cancer Institute
State of Nebraska
Publisher
American Chemical Society (ACS)
Subject
Drug Discovery,Molecular Medicine
Link
http://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.6b00150
Reference167 articles.
1. FDA-approved small-molecule kinase inhibitors
2. A Novel Pyrazolo[1,5-a]pyrimidine Is a Potent Inhibitor of Cyclin-Dependent Protein Kinases 1, 2, and 9, Which Demonstrates Antitumor Effects in Human Tumor Xenografts Following Oral Administration
3. Zheleva, D.Novel purine CDK inhibitors and their therapeutic potential.www.molonkol.org/_data/section-1/60.pdf, 2010.
4. SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples
5. BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
Cited by 118 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Newly developed preclinical models reveal broad‐spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide;Cancer Science;2023-11-03
2. Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy;Acta Pharmaceutica Sinica B;2023-09
3. Off-target pharmacological activity at various kinases: Potential functional and pathological side effects;Journal of Pharmacological and Toxicological Methods;2023-09
4. One‐pot synthesis of indolizin‐1‐yl‐pyrimidines from ethyl 3‐(3‐ethoxy‐3‐oxopropanoyl) indolizine‐1‐carboxylate, DMF‐DMA and amidines;Journal of Heterocyclic Chemistry;2023-08-13
5. New Imadazopyrazines with CDK9 Inhibitory Activity as Anticancer and Antiviral: Synthesis, In Silico, and In Vitro Evaluation Approaches;Pharmaceuticals;2023-07-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3